In this episode, we look at a life sciences instrumentation company in the genome analysis space called Bionano Genomics (BNGO.Q). The company develops and markets the Saphyr system, a platform used for ultra-sensitive and ultra-specific structural variation detection. This Optical Genome Mapping (OGM) platform can detect these large Structural Variations responsible for genetic diseases and can reveal them at sensitivities as high as 99%, with false-positive rates below 2%. But how well has the Saphyr worked BNGO so far? We look at their tech, financial statements and stock price. Tune in!
To Invest or Not: Bionano Genomics (BNGO.Q)
Latest Articles
- Standard Uranium (STND.V): Now a triple threat as Sprott goes nuclear on uranium buy
- Zefiro Methane Corp (ZEFI.CBOE): Caps orphaned oil wells, cleans the environment, and makes money
- Victory lap: Five companies we told you about and how far up they’ve gone since
- Standard Uranium (STND.V) coverage sees stock rise 90% in three days
- The promo engine is revving on Magma Silver (MGMA.V)
Top Searches
Abitibi Greenstone Belt Barrick Gold best canadian cannabis company biotech Bitcoin blockchain bullion Canada cannabis CBD China Chris Parry covid cryptocurrency DEFN.V Fraser Institute gambling Gold gold price. gold prices Greg Nolan hemp inflation interest rates investing investments lithium Lukas Kane marijuana mining money Newmont Goldcorp Nexus Gold pharmaceuticals psychedelics resources shrooms stock market stocks technology trading uranium wealth wealth creation weed
by
Leave a Reply